<DOC>
	<DOCNO>NCT02686762</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize , placebo-controlled trial involve subject diagnosis `` definite NASH '' fibrosis ( exclude cirrhosis ) determine central histopathologist . Upon successful screening , subject randomize receive either emricasan 50 mg BID emricasan 5 mg BID match placebo BID .</brief_summary>
	<brief_title>Emricasan , Caspase Inhibitor , Evaluation Subjects With Non-Alcoholic Steatohepatitis ( NASH ) Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Caspase Inhibitors</mesh_term>
	<criteria>1 . Male female subject 18 year old , able provide write informed consent , able understand willing comply requirement study 2 . Histological evidence definite NASH base NASH CLinical Research Network ( CRN ) criterion , confirm central histopathologist , liver biopsy obtain 6 month prior Day 1 3 . NAFLD Activity Score ( NAS ) 4 great score least 1 component NAS ( steatosis score 03 , lobular inflammation score 03 , ballooning score 02 ) 4 . Fibrosis stage 1 ( limited 20 % subject ) , stage 2 , stage 3 use NASH CRN Histologic Scoring System . Subjects fibrosis stage 1 must also diabetes mellitus metabolic syndrome 5 . Willingness utilize effective contraception ( male females childbearing potential ) Screening 4 week last dose study drug 6 . If vitamin E pioglitazone , subject must stable dose least 3 month prior biopsy ( whether historical qualify biopsy ) 1 . Current history significant alcohol consumption , define 20 g/day female 30 g/day male average , inability reliably quantify alcohol consumption base investigator 's judgement 2 . Use follow drug ( may potential hepatotoxic effect ) within 6 month prior Day 1 : amiodarone , methotrexate , tamoxifen , valproic acid , estrogens dos great use hormone replacement contraception , anabolic steroid , systemic glucocorticoid 4 week dose great replacement dose 3 . Uncontrolled diabetes ( HbA1c ≥9 % ) within 60 day prior Day 1 4 . Presence cirrhosis liver biopsy ( fibrosis stage 4 base central histopathologist reading ) 5 . Hepatitis fibrosis likely related etiology NASH : 1. alcoholic steatohepatitis 2. autoimmune hepatitis 3. hepatitis B virus ( HBV ) infection 4. hepatitis C virus ( HCV ) infection 5. primary biliary cirrhosis 6. primary sclerosing cholangitis 7 . Wilson 's disease 8. alpha1antitrypsin deficiency 9. hemochromatosis iron overload 10. druginduced liver disease 11. biliary liver disease 6 . ALT AST &gt; 5 time upper limit normal ( ULN ) total bilirubin &gt; 1.5 time ULN screening ( unless subject elevate total bilirubin due Gilbert 's documented medical record ) 7 . Alphafetoprotein &gt; 200 ng/mL 8 . Hemoglobin &lt; 10 g/dL 9 . White blood cell count &lt; 2.0 x 10^3/mm3 10 . Estimated creatinine clearance &lt; 30 mL/min 11 . Current use follow medication consider significant inhibitor OATP1B1 OATP1B3 transporter : atazanavir , cyclosporine , eltrombopag , gemfibrozil , indinavir , lopinavir , ritonavir , rifampin , saquinavir , simeprevir , telaprevir , tipranovir , combination medication 12 . Symptoms biliary colic , e.g . due symptomatic gallstone , within last 6 month , unless resolve follow cholecystectomy 13 . Inability safely obtain liver biopsy 14 . Known human immunodeficiency virus ( HIV ) infection 15 . Weight loss ≥ 10 % within 6 month Day 1 16 . Use controlled substance ( include inhale injected drug ) nonprescribed use prescription drug within 1 year screen point interfere subject 's ability comply study procedure study drug administration investigator 's judgement 17 . History active malignancy , successfully treat curative intent believe cured 18 . Significant systemic major illness liver disease opinion investigator would preclude subject participate completing study , include limited acute coronary syndrome stroke within 6 month screen major surgery within 3 month screen 19 . History presence clinically concern cardiac arrhythmia , prolongation Screening ( pretreatment ) QTcF interval &gt; 480 millisecond ( msec ) 20 . Prior plan ( time frame study ) bariatric surgery 21 . If female : plan known pregnancy , positive urine serum pregnancy test , lactating/breastfeeding 22 . Previous treatment emricasan active investigational medication clinical trial within 6 month prior Day 1 23 . Prior liver transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NASH</keyword>
</DOC>